Pipeline Moves: Novartis Phase I/Ib cancer trial terminates, further study chances drop
The Clinical Trials Arena team also investigate assets in radiculopathy, solid tumours, radicular pain, autoimmune disorders and inflammation.
By
Central Nervous System
Latest in
Central Nervous System
Karuna reports positive Phase III KarXT data in schizophrenia
KarXT offered a statistically significant and clinically meaningful 9.6-point decline in the PANSS total score versus placebo.
Pipeline Moves: Phase II gout trial termination slashes advancement prospects
We also review assets in allergic rhinitis, anorexia, paroxysmal nocturnal haemoglobinuria, and polyomavirus infections.
By
Physicians highlight need for improved treatments targeting key symptoms of ASD
Most currently approved ASD therapies are prescribed off-label, resulting in significant opportunity for developers in the market.
By
Alzheimer’s disease: charting amyloid theory trials amidst another controversy
After reports of possible image fabrication in studies supporting the amyloid theory for Alzheimer’s disease, we break down the slate…
By
Cortexyme concludes Phase I Alzheimer’s disease trial
Data from the SAD portion of the Phase I trial showed that COR588 was well-tolerated.
Pipeline Moves: Phase II essential tremor trial completes, advancement prospects jump
Clinical Trials Arena team also look into trials in glioblastoma multiforme, open-angle glaucoma, and hives.
By
Vertex to advance VX-548 to Phase III acute pain trial
The Phase III programme will have two trials to assess the safety and efficacy of VX-548 to treat moderate to…